2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1304

Efficacy and Safety of Hylan G-F 20 versus Intra-Articular Corticosteroids in Patients with Knee Osteoarthritis: A Systematic Literature Review, Meta-Analysis, and Network Meta-analysis
Abstract Number: 1305

Quality Improvement in Diagnostic and Therapeutic Arthrocentesis in the Flexed Knee Using Pneumatic Compression of the Suprapatellar Bursa
Abstract Number: 1306

Risk Factors for Pain After Total Joint Replacement in Osteoarthritis: Different Pain Measures, Distinct Predictors?
Abstract Number: 1307

A Prospective, Multi-center, Randomized, Clinical Trial Comparing the Effectiveness and Safety of Cooled Radiofrequency Ablation versus a Single Injection of Hyaluronic Acid in the Management of OA Knee Pain
Abstract Number: 1308

Subject Enrichment Criteria for Phase 3 Studies of Lorecivivint (SM04690), a Potential Disease-Modifying Knee Osteoarthritis Drug: A Post Hoc Study on the Effects of Baseline Comorbid Pain and Joint Space Width on Patient-Reported Outcomes
Abstract Number: 1309

Concordance of Baseline Pain Measures (Across Two Reporting Instruments) Influences Treatment Effect: Post Hoc Analysis of a Phase 3 Randomized Controlled Trial of Triamcinolone Acetonide Extended-Release in Patients with Knee Osteoarthritis
Abstract Number: 1310

Osteoarthritis: What’s in a Name?
Abstract Number: 1311

Prevalence of Symptomatic Axial Osteoarthritis and Poliarticular Phenotypes in Spain: EPISER 2016 Study
Abstract Number: 1312

Knee Morphology Associates with Tibio-Femoral and Patello-Femoral Osteoarthritis: A Case-Control Study
Abstract Number: 1313

Readmissions After Staged vs Simultaneous Bilateral Total Knee Replacements (TKR)
Abstract Number: 1314

Patient-Specific Reference Values for Objective Physical Function Tests: Cross-Sectional Analysis Using Data from the Osteoarthritis Initiative
Abstract Number: 1315

Relation of MRI-detected Structural Damage in the Patellofemoral Joint to Pain and Performance Based Function: The MOST Study
Abstract Number: 1316

Frail Patients Have Less Pain After Total Hip Replacement
Abstract Number: 1317

Frail Patients Have Worse Function After Total Knee Replacement
Abstract Number: 1318

In an International, Multicentre, Double-blind, Randomised Study in Knee Osteoarthritis Patients, Diacerein Was Found as Effective as Celecoxib in Reducing Pain and Disease Symptoms

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].